Eczema study uncovers potential new treatment path

NCT ID NCT04133506

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looked at a specific immune pathway (PGE2/IL22/IL17) in people with eczema to see if it plays a role in the disease. Researchers collected skin and blood samples from 38 participants, including those with eczema, psoriasis, and healthy volunteers. The goal was to identify which patients might benefit from future treatments targeting this pathway.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • QMRI

    Edinburgh, United Kingdom